Like I’ve mentioned before, I tend not to trust anyone in life, especially someone on an investor board. Does Lawman own that many warrants and/or shares? Maybe, maybe not.

But he does make valid points about all aspects of CYDY, from management to leronlimab to financing. Combo is nearly a given and will eventually bring in revenue, as will Mono and the prostate test. It’s just a matter of time and more funding. Cancer is the lost promising and could bring in the largest increase in market value.